

# Poster Discussion

**Thursday, Sept. 2**

**Annex Hall**

---

**Time: 13:00-14:00**

## **Epidemiology- I**

**Chair: Claudio Bianchi**

(Center for the Study of Environmental Cancer - Italian League against Cancer, Italy)

**P01-1 Environmental asbestos related diseases: a South African experience**

**Jill Murray**

(National Institute for Occupational Health, National Health Laboratory Service, South Africa)

**P01-2 Mesothelioma incidence and survival in UK cancer networks and regions**

**Michael Peake**

(National Cancer Intelligence Network, UK)

**P01-3 Genoa and Trieste, Italy: malignant mesothelioma in two coastal areas**

**Claudio Bianchi**

(Center for the Study of Environmental Cancer - Italian League against Cancer, Italy)

**P01-4 Malignant mesothelioma in nonagenarian people**

**Claudio Bianchi**

(Center for the Study of Environmental Cancer - Italian League against Cancer, Italy)

**P01-5 Estimation of the effects of temporal patterns of occupational asbestos exposure on the risk of pleural mesothelioma: results from a French pooled case-control study**

**Aude Lacourt**

(Laboratoire Sante Travail Environnement EA 3672, Equipe Associee en Sante Travail, ISPED, Universite Victor Segalen Bordeaux 2, France)

**P01-6 Epidemiology of malignant pleural mesothelioma in Yekaterinburg**

**Sergey Kashanskiy**

(Yekaterinburg Medical Research Center, Russia)

## **Epidemiology- II**

**Chair: Soon-Hee Jung**

(Department of Pathology, Yonsei University Wonju College of Medicine, Korea)

**P02-1 Magnitude of misclassification of current address which is used as environmental asbestos exposure surrogate**

**Dongmug Kang**

(Pusan National University, Research Center for Asbestos Related Diseases, Korea)

- P02-2**    **The first nationwide survival analysis of Japanese mesothelioma patients from “Vital Statistics of Japan”**  
**Keisuke Aoe**  
(Department of Medical Oncology and Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, Japan)
- P02-3**    **Years of potential life lost due to malignant mesothelioma: a global assessment**  
**Giang Le**  
(Department of Environmental Epidemiology, University of Occupational and Environmental Health, Japan)
- P02-4**    **Cancelled**
- P02-5**    **Difficulties experienced by mesothelioma patients in Japan**  
**Yasuko Nagamatsu**  
(St Luke’s College of Nursing, Japan)
- P02-6**    **Official acknowledgement method of mesothelioma patients by the Asbestos-Related Health Damage Relief Law in Japan**  
**Hirotao Miura**  
(The Department of Respiratory Medicine, Yokosuka General Hospital, Japan)
- P02-7**    **Estimation of lifetime direct medical cost of pleural mesothelioma in Taiwan**  
**Lukas Lee**  
(Division of Environmental Health and Occupational Medicine, National Health Research Institutes, Taiwan)

## **Oncogenesis- I**

- Chair: Seiji Yano**  
(Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Japan)
- P03-1**    **MET receptor tyrosine kinase as a potential therapeutic target in malignant mesothelioma**  
**Nicholas Campbell**  
(Chicago University, USA)
- P03-2**    **Involvement of adaptor protein Crk in malignant features of human mesothelioma**  
**Mishie Tanino**  
(Laboratory of Cancer Research, Department of Pathology, Hokkaido University Graduate School of Medicine, Japan)
- P03-3**    **Oncogenic effect of Cul4A in mesothelioma development**  
**Ming-Szu Hung**  
(Department of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Taiwan)
- P03-4**    **Analysis of lipoxygenase pathways in malignant pleural mesothelioma**  
**Vijay Agarwal**  
(Cancer Biology Proteomics Group, Postgraduate Medical Institute, University of Hull, UK)

**P03-5 YAP induces malignant mesothelioma cell proliferation via induction of CCDN1 expression**

**Tetsuya Mizuno**

(Division of Molecular Oncology, Aichi Cancer Center Research Institute, Japan)

**P03-6 Expression and functional analysis of Hairy Enhancer of Split 1 (HES1) in human malignant mesothelioma cell lines**

**Hideki Murakami**

(Division of Molecular Oncology, Aichi Cancer Center Research Institute, Japan)

**Oncogenesis- II**

**Chair: Steven Gray**

(Department of Clinical Medicine, Trinity College Dublin, Ireland)

**P04-1 RON/MST1R, a receptor tyrosine kinase expressed in malignant pleural mesothelioma**

**Steven Gray**

(Department of Clinical Medicine, Trinity College Dublin, Ireland)

**P04-2 All-trans-retinoic acid inhibits tumor growth of malignant pleural mesothelioma in mice**

**Chiharu Tabata**

(Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Japan)

**P04-3 Novel mechanism implicated in asbestos-induced malignant mesothelioma**

**Li Jiang**

(Department of Pathology and Biological Responses, Nagoya University, Japan)

**P04-4 Epigenetic inactivation of tumour suppressor genes by DNA methylation in malignant mesothelioma**

**Yuen Yee Cheng**

(Asbestos Diseases Research Institute, University of Sydney, Australia)

**P04-5 Genomic profile of human malignant pleural mesothelioma: A CGH-array comparison between primary tumors and cells in culture**

**Didier Jean**

(INSERM UMR 674, "Functional Genomics of Solid Tumors", IUH, Université Paris Descartes, France)

**Oncogenesis- III**

**Chair: Tomoko Hashimoto-Tamaoki**

(Department of Genetics, Hyogo College of Medicine, Japan)

**P05-1 Frequent deletions in 3p21.1 region in malignant mesothelioma cell lines established from Japanese patients**

**Yoshie Yoshikawa**

(Department of Genetics, Hyogo College of Medicine, Japan)

**P05-2 Knockdown of ZEB1, a master epithelial mesenchymal transition (EMT) inducing gene, suppresses growth of pleural mesothelioma cell lines**

**Mihoko Horio**

(Aichi Cardiovascular and Respiratory Center, Japan)

**P05-3 Association of asbestos exposure and cigarette smoking with gene abnormalities in lung adenocarcinomas in Japan**

**Hironori Ninomiya**

(Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Japan)

**P05-4 Activated leukocyte cell adhesion molecule is involved in motility and invasion of malignant pleural mesothelioma**

**Futoshi Ishiguro**

(Division of Molecular Oncology, Aichi Cancer Center Research Institute, Japan)

**P05-5 Identification of tumor initiating cells in malignant pleural mesothelioma**

**Claudia Frei**

(Laboratory of Molecular Oncology, Zurich University Hospital, Switzerland)

## **Asbestos**

**Chair: Yasuo Morimoto**

(Department of Occupational Pneumology, University of Occupational and Environmental Health, Japan)

**P06-1 Analysis of early lesions in rats after intraperitoneal administration of nanofibers**

**Miho Mizoi**

(Dept. Pub. Health, Grad.Sch.Nutr.Sci., Sagami Women's Univ., Japan)

**P06-2 Asbestos body analysis in patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy**

**Kazunori Okabe**

(Division of Thoracic Surgery, National Hospital Organization, Yamaguchi Ube Medical Center, Japan)

**P06-3 Trends in asbestos and nonasbestos fiber concentrations in the lung tissues of Japanese patients with mesothelioma**

**Kiyoshi Sakai**

(Nagoya City Public Health Research Institute, Japan)

**P06-4 Asbestos fiber concentration in lung tissues resected for malignant pleural mesothelioma**

**Noriyasu Usami**

(Division of Thoracic Surgery, Nagoya University Graduate School of Medicine, Japan)

## **Immunology**

**Chair: Yasuhiko Nishioka**

(Department of Respiratory Medicine and Rheumatology Institute of Health Biosciences, The University of Tokushima Graduate School, Japan)

**P07-1 Human MT-2 cell line displays enhanced suppressive function by chronic exposure to asbestos**

**Megumi Maeda**

(Department of Hygiene, Kawasaki Medical School, Japan)

**P07-2 The effects of continuous long-term exposure to asbestos, chrysotile and crocidolite on HTLV-1 immortalized human T cell line, MT-2**

**Takemi Otsuki**

(Department of Hygiene, Kawasaki Medical School, Japan)

**P07-3 Suppressive effect of asbestos-exposure on the differentiation of human cytotoxic T lymphocytes, accompanied with decreases in IFN- $\gamma$  and TNF- $\alpha$**

**Naoko Kumagai**

(Department of Hygiene, Kawasaki Medical School, Japan)

**P07-4 Pleural mesothelioma instigates tumor associated fibroblasts to promote progression via malignant cytokine network**

**Qi Li**

(Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Japan)

**P07-5 Decrease in NKp46 on NK cells upon exposure to asbestos, a possible marker to monitor anti-tumor immunity**

**Yasumitsu Nishimura**

(Department of Hygiene, Kawasaki Medical School, Japan)

## **Animal models**

**Chair: Prasad Adusumilli**

(Memorial Sloan-Kettering Cancer Center, USA)

**P08-1 Mesothelioma xenografts developed in the immune deficient mice and the clinical relevance**

**Ming-Sound Tsao**

(Ontario Cancer Institute/Princess Margaret Hospital, University Health Network, University of Toronto, Canada)

**P08-2 Location matters: biological significance of pleural microenvironment in mesothelioma murine models**

**Elliot Servais**

(Memorial Sloan-Kettering Cancer Center, USA)

**P08-3 Antioxidants are ineffective for prevention of mesothelioma in the MexTAg asbestos-induced mouse mesothelioma model**

**Cleo Robinson**

(National Centre for Asbestos Related Diseases, University of Western Australia, Australia)

**P08-4 Microenvironment-dependent mesenchymal-to-epithelial transition in a xenograft model of malignant mesothelioma**

**Eva Ramqvist**

(Department of Clinical Pathology/Cytology, Karolinska University Hospital, Sweden)

**P08-5 A conditional mouse model for spontaneous malignant pleural mesothelioma, and its detection by bioluminescence**

**Françoise Le Pimpec-Barthes**

(INSERM UMR 674, "Functional Genomics of Solid Tumors" , IUH, Université Paris Descartes, France)

**P08-6 The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice**

**Wei Wang**

(Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Japan)

**P08-7 Establishment of *in vivo* fluorescence imaging in mouse models of malignant mesothelioma**

**Shuji Kubo**

(Laboratory of Host Defenses, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Japan)

## **Pathology- I**

**Chair: Lucian Chirieac**

(Department of Pathology, Brigham and Women's Hospital, USA)

**P09-1 Expression of survivin and effects of survivin siRNA transfection on mesothelioma cell lines**

**Looniva Shrestha**

(Department of Pathology, Hiroshima University, Japan)

**P09-2 How to diagnose cytokeratin-negative anaplastic mesotheliomas?**

**Noriko Kimura**

(Department of Clinical Research Pathology Section, National Hospital Organization Hakodate Hospital, Japan)

**P09-3 Genomic gains and losses in malignant mesothelioma demonstrated by FISH analysis of paraffin-embedded tissues**

**Maiko Takeda**

(Department of Diagnostic Pathology, Nara Medical University School of Medicine, Japan)

**P09-4 Molecular pathology of lung carcinoma in asbestos-exposed workers compared to mesothelioma**

**Pascal Andujar**

(Hôpital Intercommunal de Créteil, France)

**P09-5 Utility of immunohistochemistry in distinguishing between benign and malignant mesothelial proliferations**

**Kei Kushitani**

(Department of Pathology, Graduate School of Biomedical Sciences, Hiroshima University, Japan)

## **Pathology-II**

**Chair: Vishwa Jeet Amatya**

(Department of Pathology, Hiroshima University Graduate School of Biomedical Sciences, Japan)

**P10-1 The trial of differentiation grading of epithelioid mesothelioma with reference to its clinicopathological significance**

**Yukio Takeshima**

(Department of Pathology, Graduate School of Biomedical Sciences, Hiroshima University, Japan)

**P10-2 Morphologically-based grading of epithelial malignant pleural mesothelioma**

**Gina Cunto-Amesty**

(Department of Pathology, Brigham and Women's Hospital, USA)

**P10-3 The accuracy of pretreatment biopsy of pleural malignant mesothelioma in predicting histopathologic type in the extrapleural pneumonectomy specimen**

**Maria McIntire**

(Department of Pathology, Brigham and Women's Hospital, USA)

**P10-4 Re-evaluation of malignant mesothelioma: similar results in a Norwegian and a Japanese study despite of different approaches**

**Helmut Sandeck**

(Department of Pathology and Medical Genetics, St. Olav University Hospital, Norway)

**P10-5 Extent of the sarcomatoid component is an independent predictor of survival in malignant mesothelioma**

**Mathias Hofer**

(Department of Pathology, Brigham and Women's Hospital, USA)

**P10-6 TLE1 expression in malignant mesothelioma: A potential pitfall in the immunohistochemical evaluation of pleuropulmonary sarcomatoid tumors**

**Joyce Ou**

(Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, USA)

## **Pathology-III**

**Chair: Tohru Tsujimura**

(Department of Pathology, Hyogo College of Medicine, Japan)

**P11-1 Patterns of lymph node spread to N2 nodes predicts survival in patients with biphasic pleural malignant mesothelioma (MM)**

**Maria McIntire**

(Department of Pathology, Brigham and Women's Hospital, USA)

**P11-2 Malignant pleural mesothelioma with tongue metastasis: more common than one would think?**

**Astero Klabatsa**

(Barts Mesothelioma Research, Department of Medical Oncology, St Bartholomews Hospital, Barts and The London Queen Marys Medical School, UK)

- P11-3**     **Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin lymphoma**  
**Justine Barletta**  
(Department of Pathology, Brigham and Women's Hospital, USA)
- P11-4**     **Desmoplastic malignant mesothelioma: a clinical review of five pathologically diagnosed cases**  
**Ryo Okuda**  
(Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan)
- P11-5**     **Cancelled**
- P11-6**     **Importance of clinical manifestations for differential diagnosis between sarcomatoid carcinoma and malignant mesothelioma**  
**Per Fredrik Ekholdt**  
(The Department of Internal Medicine, Sykehuset Ostfold Helsefortak Fredrikstad, Norway)
- P11-7**     **Long-term survival of stage IV pleural mesothelioma presenting with retroperitoneal mass following multimodality treatment**  
**Joseph Friedberg**  
(Penn Mesothelioma and Pleural Disease Program Coordinator, Thoracic Surgery Clinical Practice and Research Coordinator, USA)

## **Pathology-IV**

**Chair: Kunimitsu Kawahara**

(Department of Pathology, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Japan)

- P12-1**     **Expression and localization of matrix metalloproteinase 9 (MMP-9) in mesothelioma cells and reactive mesothelial cells**  
**Hironori Katayama**  
(Department of Pathology, Nippon Medical school, Tama-Nagayama Hospital, Japan)
- P12-2**     **Immunocytochemistry of CD146 is useful for discrimination between malignant pleural mesothelioma and reactive mesothelium in effusion cytology**  
**Ayuko Sato**  
(Department of Pathology, Hyogo College of Medicine, Japan)
- P12-3**     **Molded mesothelioma cells with hump-like cytoplasmic process in effusion cytology**  
**Shinji Hamakawa**  
(Department of Central Laboratory, Showa General Hospital, Japan)
- P12-4**     **Collagenous stroma in body fluid cytology -Characteristic features and clinicopathological significance-**  
**Sakae Hata**  
(Department of Pathology, Kawasaki Medical School Hospital, Japan)
- P12-5**     **Analysis of orangeophilic cells in effusion cytology**  
**Toshiaki Kamei**  
(Division of Pathology, Yamaguchi Grand Medical Center, Japan)

**P12-6 Cytodiagnosis of malignant mesothelioma in effusion cytology - cell characteristic features and immunocytochemistry-**

**Toshiaki Kamei**

(Division of Pathology, Yamaguchi Grand Medical Center, Japan)

**P12-7 Diagnosis of malignant pleural mesothelioma: Comparison between pleural effusion cytology and pleural biopsy**

**Seiji Matsumoto**

(Department of Thoracic Surgery, Hyogo College of Medicine, Japan)

**Biomarkers- I**

**Chair: Per Fredrik Ekholdt**

(The Department of Internal Medicine, Sykehuset Ostfold Helsefortak Fredrikstad, Norway)

**P13-1 Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion**

**Shoutaro Tsuji**

(Division of Cancer Therapy, Kanagawa Cancer Center Research Institute, Japan)

**P13-2 Diagnostic markers for malignant pleural mesothelioma: Serum antibody against antigens recognized by antibodies produced from tumor infiltrating B cells**

**Yoshiki Shigematsu**

(2nd Department of Surgery, University of Occupational and Environmental Health, Japan)

**P13-3 Circulating tumor cells (CTCs) in the diagnosis of malignant pleural mesothelioma (MPM)**

**Kazue Yoneda**

(Department of Thoracic Surgery, Hyogo College of Medicine, Japan)

**P13-4 Clinical significance of serum VEGF in malignant pleural mesothelioma**

**Chiharu Tabata**

(Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Japan)

**P13-5 CD9 expression in mesothelioma: A correlation with clinicopathological factors and survival of patients**

**Vishwa Jeet Amatya**

(Department of Pathology, Hiroshima University Graduate School of Biomedical Sciences, Japan)

**Biomarkers- II**

**Chair: Fumihiko Tanaka**

(Department of Thoracic Surgery, Hyogo College of Medicine, Japan)

**P14-1 Novel clinical role of angiotensin-1 in malignant pleural mesothelioma**

**Noriko Hirayama**

(Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Japan)

**P14-2 Platelet-derived growth factor (PDGF) in pleural effusion of malignant pleural mesothelioma and cancerous pleurisy due to lung cancer**

**Kunihiro Tamura**

(Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Japan)

**P14-3 A battery of biomarkers from effusions improve sensitivity for the diagnosis of malignant mesothelioma**

**Filip Mundt**

(Department of Laboratory Medicine, Karolinska University Hospital, Sweden)

**P14-4 Soluble mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis**

**Kevin Hollevoet**

(Department of Respiratory Medicine, Ghent University Hospital, Belgium)

**P14-5 Serum mesothelin levels in asbestos exposed populations**

**Manlio Mencoboni**

(Oncology Unit, Villa Scassi Hospital, Italy)

**Biomarkers-III**

**Chair: Hugo Schouwink**

(Department of Pulmonary Diseases Medisch Spectrum Twente, Enschede, The Netherlands)

**P15-1 Serum N-ERC as a useful biomarker for mesothelioma treatment**

**Takanori Mori**

(Department of Respiratory Medicine, Juntendo University, School of Medicine, Japan)

**P15-2 Megakaryocyte potentiating factor is effective for the differential diagnosis of malignant pleural mesothelioma**

**Kazuki Shimada**

(National Institute of Biomedical Innovation, Laboratory for Immune Signal, Japan)

**P15-3 Role of SMRP, osteopontin and CA-125 for early diagnosis of malignant pleural mesothelioma**

**Katrina Rey-McIntyre**

(University of Toronto, Canada)

**P15-4 Gene expression ratio-based diagnostic and predictive tests using fine needle aspiration biopsies in malignant pleural mesothelioma**

**Assunta De Rienzo**

(Division of Thoracic Surgery and the International Mesothelioma Program, Brigham and Women's Hospital, and Harvard Medical School, USA)

**P15-5 Optimization of mesothelioma gene ratio tests for paraffin-embedded tissue**

**Melissa Coleman**

(Division of Thoracic Surgery and the International Mesothelioma Program, Brigham and Women's Hospital, and Harvard Medical School, USA)

## **Imaging- I**

Chair: TBA

**P16-1 Computed tomographic assessment of apical involvement in clinical evaluation of malignant pleural mesothelioma**

**William Richards**

(Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, USA)

**P16-2 Virtual surgical planning for pleural mesothelioma. Interactive volume visualization and automated quantification of pleural tumors on a 3D stereoscopic graphics cluster**

**Nigel Parsad**

(Computation Institute, University of Chicago, USA)

**P16-3 Prognostic value of <sup>18</sup>F-FDG PET/CT in malignant pleural mesothelioma**

**Cecilia Bech**

(Department of Oncology, Finsen Centre/National University Hospital, Denmark)

**P16-4 A fusion image of PET and pleural plaque 3D-CT for the early detection of malignant pleural mesothelioma in asbestos disease**

**Tadaaki Miyamoto**

(Chiba Prefecture Medical Association for Workers, Japan)

**P16-5 CT findings of benign asbestos pleural effusion**

**Katsuya Kato**

(The Department of Radiology, Okayama University Hospital, Japan)

## **Imaging- II**

Chair: **Kazuya Kondo**

(Department of Oncological Medical Services, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan)

**P17-1 Physiologic and computed tomographic predictors of outcome following extrapleural pneumonectomy for mesothelioma**

**Saba Dhiya**

(Department of Anesthesiology, Brigham&Women's Hospital, USA)

**P17-2 Assessment of therapeutic response using FDG PET in patients with malignant pleural mesothelioma**

**Bumpei Yamaguchi**

(Department of Pulmonary Medicine, Southern Tohoku General Hospital, Japan)

**P17-3 A simple scoring system to measure the volume of disease in malignant pleural mesothelioma**

**Aparna Deshpande**

(Gelnfield Hospital, University Hospitals of Leicester, UK)

**P17-4 *In vitro* and *in vivo* photodynamic diagnosis using 5-aminolevulinic acid in malignant mesothelioma**

**Abdellah Hamed Khalil**

(Department of Oncological Medical Services, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan)

## **Treatment- I**

**Chair: Hirozo Sakaguchi**

(Department of Chest Surgery, Saitama Medical University, International Medical Center, Japan)

**P18-1 Determination of resectability aided by ventilation and perfusion imaging in patients undergoing extrapleural pneumonectomy (EPP) for malignant pleural mesothelioma**

**Tamara Tilleman**

(Division of Thoracic Surgery, Department of Surgery, Brigham and Women's Hospital, USA)

**P18-2 Surgical treatment for malignant pleural mesothelioma**

**Satoru Moriyama**

(Oncology, Immunology and Surgery, Nagoya City University Medical School, Japan)

**P18-3 Role of pleural pressure control following extra-pleural pneumonectomy during early postoperative days**

**Kenji Okita**

(Thoracic Surgery Department, Kyoto Katsura Hospital, Japan)

**P18-4 Discrepancy between clinical and pathological stages in patients undergoing extrapleural pneumonectomy for malignant pleural mesothelioma**

**Masaki Hashimoto**

(Department of Thoracic Surgery, Hyogo College of Medicine, Japan)

**P18-5 BNP is a useful biomarker for cardiac condition after EPP**

**Masaki Hashimoto**

(Department of Thoracic Surgery, Hyogo College of Medicine, Japan)

**P18-6 Intrapleural perfusion hyperthermo-chemotherapy with cisplatin in patients with malignant pleural mesothelioma**

**Hirozo Sakaguchi**

(Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Japan)

## **Treatment- II**

**Chair: Joseph Friedberg**

(University of Pennsylvania, USA)

**P19-1 Bronchopleural fistula after extrapleural pneumonectomy for pleural mesothelioma**

**Kazu Shiomi**

(Department of Thoracic Surgery, Hyogo College of Medicine, Japan)

**P19-2 The first postoperative serum creatinine value predicts the development of sustained kidney injury in patients undergoing surgical treatment for malignant**

**K Annette Mizuguchi**

(Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, USA)

- P19-3 Postoperative management of 25 patients undergoing extrapleural pneumonectomy for malignant mesothelioma**  
**Takeshi Ide**  
(Division of Intensive Care Unit, Hyogo College of Medicine, Japan)
- P19-4 Novel urinary biomarkers for the early detection of kidney injury following cytoreductive surgery and intracavitary cisplatin lavage for mesothelioma**  
**Sushrut Waikar**  
(Renal Division, Brigham&Women's Hospital, USA)
- P19-5 Replacement of the diaphragm by the latissimus dorsi muscle flap during mesothelioma resection**  
**Tomasz Grodzki**  
(Thoracic Surgery Department, Pomeranian Medical University, Szczecin, Poland)
- P19-6 Three modality treatment of malignant pleural mesothelioma**  
**Evgeny Levchenko**  
(Petrov Research Institute of Oncology, Russia)

### **Treatment-III**

**Chair: Osamu Kawamata**  
(Department of Surgery, Onomichi Municipal Hospital, Japan)

- P20-1 Adjuvant chemotherapy subsequent to extrapleural pneumonectomy for patients with malignant pleural mesothelioma is slightly beneficial**  
**Mamoru Ueda**  
(Department of Respiratory Surgery, Higashisaitama National Hospital, Japan)
- P20-2 Extrapleural pneumonectomy and medical treatment for malignant pleural mesothelioma (MPM): the role of pemetrexed**  
**Matteo Incarbone**  
(Thoracic Surgery, Istituto Clinico Humanitas, Italy)
- P20-3 Multimodality treatment with induction chemotherapy followed by an extrapleural pneumonectomy in patients with malignant pleural mesothelioma**  
**Takuro Kometani**  
(Department of Thoracic Oncology, National Kyushu Cancer Center, Japan)
- P20-4 Cancelled**
- P20-5 The study of the malignant pleural mesothelioma case that survived more than two years**  
**Osamu Kawamata**  
(Department of Surgery, Onomichi Municipal Hospital, Japan)
- P20-6 Feasibility of establishing a multidisciplinary program devoted solely to the treatment of pleural diseases**  
**Melissa Culligan**  
(University of Pennsylvania, USA)

## **Novel therapeutics- I**

**Chair: Lee Krug**  
(Memorial Sloan-Kettering Cancer Center, USA)

**P21-1 Replication-competent retrovirus vector-mediated suicide gene therapy achieves significant therapeutic efficacy against human malignant mesothelioma xenografts**

**Shuji Kubo**  
(Laboratory of Host Defenses, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Japan)

**P21-2 FGK45 immune-based treatment may cure mesothelioma in mice with or without combination with viral therapy**

**Wei Xia**  
(Hanson Institute, Royal Adelaide Hospital, SA, Australia)

**P21-3 Inhibition tumor growth of malignant pleural mesothelioma by adeno-associated viral type-8 vector expressing mda-7/IL-24**

**Yuji Minegishi**  
(Department of Internal Medicine, Division of Pulmonary Medicine, Infectious disease, and Oncology, Nippon Medical School, Japan)

**P21-4 VEGF targeting in mesothelioma treatment using an interleukin-6 signal inhibitor based on adenovirus gene delivery**

**Yasuo Adachi**  
(Laboratory of Immune Regulation, Wakayama Medical University, Japan)

**P21-5 The antitumor effect of pemetrexed combined with conditionally replicative adenovirus against human malignant pleural mesothelioma cell lines**

**Noriaki Nakagaki**  
(Research Institute for Diseases of the Chest, Kyushu University, Japan)

## **Novel therapeutics- II**

**Chair: Koichi Takayama**  
(Research Institute for Diseases of the Chest, Kyushu University, Japan)

**P22-1 Ex vivo expansion of tumor-infiltrating lymphocytes for adoptive cell therapy: a potential therapeutic option for patients with malignant pleural mesothelioma**

**Masaki Anraku**  
(Latner Thoracic Surgery Laboratories, Toronto General Research Institute, University of Toronto, Canada)

**P22-2 Targeting macrophages as a novel therapeutic approach for malignant pleural mesothelioma**

**Nikita Kolhatkar**  
(Department of Pathology, University of California, San Francisco, USA)

**P22-3 Targeted imaging and therapy of malignant mesothelioma using novel internalizing antibodies**

**Jiang He**  
(Department of Radiology & Biomedical Imaging, University of California San Francisco, USA)

**P22-4**     **Cancelled**

**P22-5**     **Estrogen receptor beta exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib**

**Giulia Pinton**

(DiSCAFF, University of Piemonte Orientale "A: Avogadro", Italy)

### **Novel therapeutics-III**

**Chair: Takashi Kijima**

(Department of Respiratory Medicine, Allergy, and Rheumatic Diseases, Osaka University of Graduate School of Medicine, Japan)

**P23-1**     **Angiogenic tissue response in patients with MPM after treatment with cisplatin, pemetrexed and axitinib**

**Wieneke Buikhuisen**

(Netherlands Cancer Institute, The Netherlands)

**P23-2**     **TSU-68 suppresses progression of malignant pleural mesothelioma through inhibiting angiogenesis in SCID mice**

**Hisatsugu Goto**

(Department of Respiratory Medicine & Rheumatology, Institute of Health Biosciences, The University of Tokushima, Japan)

**P23-3**     **SOCS-3 protein exhibits preclinical anti-tumor activity in malignant pleural mesothelioma**

**Kota Iwahori**

(Laboratory for Immune Signal, National Institute of Biomedical Innovation, Japan)

**P23-4**     **MET, EGFR and IGF1R are involved in feedback activation of AKT arising from inhibition of mTOR in malignant pleural mesothelioma (MPM): rationale for inhibitor combinations**

**Marie Brevet**

(Memorial Sloan Kettering Cancer Center, USA)

**P23-5**     **RNAi-based screening of potential chemosensitising targets for malignant mesothelioma**

**Lyn Schedlich**

(Asbestos Diseases Research Institute, Bernie Banton Centre, The University of Sydney, Australia)

**P23-6**     **TS-1 suppresses the growth of malignant pleural mesothelioma cells co-expressing dihydropyrimidine dehydrogenase and thymidine phosphorylase in an orthotopical model**

**Trung Van**

(Department of Medical Oncology, Institute of Health Biosciences, The University of Tokushima, Japan)

## **Case report- I**

**Chair: Takao Morohoshi**

(Division of Surgery, Chest Diseases Center, Yokosuka Kyou Sai Hospital, Japan)

**P24-1 Primary malignant peritoneal mesothelioma of the great omentum diagnosed by cytology of ascites: A case report**

**Kayo Inoue**

(Department of Obstetrics and Gynecology, Hyogo College of Medicine, Japan)

**P24-2 Malignant mesothelioma of the peritoneum: Case reports and immunohistochemical findings including Ki-67 expression**

**Hiroshi Hirano**

(Department of the Pathology, Nippon Steel Hirohata Hospital, Japan)

**P24-3 Pleural multicystic mesothelioma : Report of a case**

**Takekazu Iwata**

(Department of Thoracic Surgery, National Hospital Organization Chiba-East National Hospital, Japan)

**P24-4 Spontaneous chylothorax in malignant pleural mesothelioma**

**Gunnar Hillerdal**

(Lung Department, Karolinska Hospital, Sweden)

**P24-5 A case of bilateral, simultaneous pleural mesothelioma**

**Takao Morohoshi**

(Division of Surgery, Chest Disease Center, Yokosuka Kyou Sai Hospital, Japan)

**P24-6 A case of pleural malignant mesothelioma with multicyst formation, demonstrating abundant viscous liquid production and peculiar cytological findings**

**Hiroshi Sonobe**

(Department of Laboratory Medicine, Chugoku Central Hospital, Japan)

## **Case report- II**

**Chair: Seiki Hasegawa**

(Department of Thoracic Surgery, Hyogo College of Medicine, Japan)

**P25-1 Collision tumor composed of malignant pleural mesothelioma and primary lung cancer: A case report and array-based study**

**Yukiko Tabata**

(Department of Surgical Pathology, Hokkaido University Hospital, Japan)

**P25-2 Post-irradiation pericardial malignant mesothelioma: report of an autopsy case and review of the literature**

**Matyas Bendek**

(Department of Pathology, Szt. Borbala Hospital, Hungary)

**P25-3 Pulmonary metastases from malignant mesothelioma of the tunica vaginalis testis: A case report**

**Tomohito Saito**

(Department of Thoracic and Cardiovascular Surgery, Kansai Medical University Hirakata Hospital, Japan)

**P25-4 Malignant pleural mesothelioma with long-term temporary tumor disappearance of a local relapse after surgery: a unique case report**

**Masahiko Higashiyama**

(Department of Thoracic Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan)

**P25-5 Acquired pemetrexed and carboplatin resistance in a long-term survivor of mesothelioma: a case report including gene expression findings**

**Oluf Roe**

(Department of Oncology, St. Olavs Hospital, University Hospital of Trondheim, Norway)

**P25-6 A unique case of malignant pleural mesothelioma with angiosarcomatous differentiation**

**Astero Klabatsa**

(Department of Medical Oncology, St Bartholomews Hospital, Barts and The London Queen Marys Medical School, UK)

**Case report-III**

**Chair: Salih Emri**

(Department of Chest Diseases, Hacettepe University Faculty Medicine, Turkey)

**P26-1 Primary intra-hepatic malignant mesothelioma accompanying with multiple lymphadenopathies due to acid-fast bacilli: A case report**

**Noriko Inagaki**

(The First Department of Internal Medicine, Kansai Medical University, Japan)

**P26-2 Localized malignant pleural mesothelioma**

**Shusai Yamada**

(Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Japan)

**P26-3 A case report of recurrent malignant pleural mesothelioma with long-term disease control after extrapleural pneumonectomy**

**Keita Fujii**

(The Division of Surgery, Chest Disease Center, Yokosuka Kyosai Hospital, Japan)

**P26-4 Simultaneous presentation of pericardial mesothelioma and chronic lymphocytic leukemia**

**Takuya Oyakawa**

(Respiratory Medicine, Hiroshima City Hospital, Japan)

**P26-5 Ultrasonography guided drainage and hormonal therapy in the treatment of recurrent benign multicystic peritoneal mesothelioma : a case report**

**Salih Emri**

(Department of Chest Diseases, Hacettepe University Faculty of Medicine, Turkey)

**P26-6 A difficult case to diagnosis of malignant pleural mesothelioma by medical thoracoscopy**

**Yumeko Hayashi**

(Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine, Japan)